In these hard economic times, when you hear anybody in biotechnology say it's "not all about cash," you might suspect the speaker of being na ve or disingenuous. And when such words come out of the straitened genomics sector, they sound even much more suspicious. (BioWorld Financial Watch)
Several months after the company cut three late-stage programs, Chiron Corp. has set about the business of building its pipeline, nailing down a small-molecule partnership with GlaxoSmithKline plc to fuel research in the melanocortin 4 receptor pathway. (BioWorld Today)
Year-end retrospectives aside, taking the figurative pulse of an industry as large and varied as biotechnology is anything but easy. But during what everybody acknowledges were tight economic times, a notable trend was the continued interest by venture capital, especially in the field of anti-infectives. (BioWorld Financial Watch)
